Latest blog articles
-
Greece emerged as the EU’s poster child in the fight against Covid-19 during the first few months of the pandemic. Its approach, while effective, is not beyond reproach. We analyse two such contested areas of Covid-19 regulation: permits of movement obtained through SMS, and restrictions to the...
-
Lack of fair responsibility sharing in asylum is one of the thorniest policy issues currently facing the EU. The EU’s responsibility allocation system, underpinned by the so-called Dublin Regulation, as designed undermines fair sharing of responsibility between the Member States. It allocates most...
-
The New Pact and EU Agencies: an ambivalent approach towards administrative integration.
-
How do we guarantee access to COVID-19 vaccines and therapies, and secure health-related human rights for all? We’ve heard a string of promises in the race for new vaccines and therapies.
-
Stay at home. Wash your hands frequently with soap and water. These simple indications could help save lives and flatten the coronavirus curve. Unfortunately, things are not so simple for the almost 39,000 asylum-seeking men, women, and children, among them thousands of unaccompanied children...
-
It’s been almost a month since the COVID-19 pandemic has drastically changed the way we live and work. Now that we are more used to, in a manner of speaking, the extraordinary measures to curtail the rampant spread of the virus, it’s time to seriously consider, and openly discuss, this crisis’...
-
EU agencies are now at the forefront of policy implementation in EU’s migration, asylum and external border control policies for two primary reasons: to overcome the policy implementation gap and enhance interstate solidarity.
-
Authors may sentence fictional characters to death to counter unwanted transformation of their characters. The authorship that copyright vests in authors grants them indisputable authority over their creations, so that their characters do not die from users’ transformation.
-
Globally the majority of health-related R&D is invested in medicines with substantial guaranteed returns, yet what is missing is extensive R&D targeted at diseases overwhelmingly prevalent in developing countries. This threatens long-term availability of medicines and treatment options for these...